PMID- 30543917
OWN - NLM
STAT- MEDLINE
DCOM- 20191202
LR  - 20191202
IS  - 1521-7035 (Electronic)
IS  - 1521-6616 (Linking)
VI  - 199
DP  - 2019 Feb
TI  - Autoimmune interstitial lung disease in Latin-America.
PG  - 52-56
LID - S1521-6616(18)30723-X [pii]
LID - 10.1016/j.clim.2018.12.013 [doi]
AB  - Information about the prognosis and natural history of autoimmune interstitial 
      lung diseases (Ai-ILD) is limited. The aim of the study was to evaluate the 
      characteristics of patients diagnosed with Ai-ILD in Latin-America. We conducted 
      an ambispective multicenter cohort study in 25 centers of Argentina, Colombia, 
      and Uruguay between January 2015 and April 2018. Participants were included in 
      the study if they had diagnosis of Ai-ILD performed by a multidisciplinary team. 
      Patients were classified into the following sub-groups: connective tissue 
      disease-associated ILD (ILD-CTD), interstitial pneumonia with autoimmune features 
      (IPAF), and positive antineutrophils cytoplasmatic antibodies associated ILD 
      (ILD-ANCA). All images were reviewed by a blinded thoracic radiologist. Out of 
      the 381 patients included during the study period, 282 (74%; 95% CI; 69.39-78.16) 
      were women. Mean age was 58 years old (SD 16). Three-hundred and twenty-five 
      (85.1%; 95% CI 81.39-88.5) patients were classified as ILD-CTD (rheumatoid 
      arthritis 31%, systemic sclerosis 29%, dermatomyositis 15%). Thirty-six patients 
      were classified as IPAF (9.5%; 95% CI 6.9-12.8), and 13 (3.5%; 95% CI 2-5.75) as 
      ILD-ANCA. Fifty percent of patients (95% CI 45.12-55.43) had a mild decrease of 
      the forced vital capacity at the time of diagnosis. The most common treatment 
      strategy was the combination of steroids and cyclophosphamide (30.1%; 95% CI 
      25.32-35.34) followed by azathioprine (20,3%; 95% CI 16.32-25.14). In conclusion, 
      to the best of our knowledge, this is the first study to evaluate the 
      characteristics and treatment strategies used in patients affected by Ai-ILD in 
      Latin-America. Future studies should to evaluate the prognosis and impact of 
      current treatment strategies in patients with Ai-ILD.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Vivero, F
AU  - Vivero F
AD  - Autoimmune Diseases Unit, Hospital Privado de Comunidad, Mar del Plata, 
      Argentina.. Electronic address: florenciavivero82@gmail.com.
FAU - Campins, F
AU  - Campins F
AD  - Respiratory Medicine, Hospital Privado de Comunidad, Mar del Plata, Argentina.
FAU - Lancellotti, D
AU  - Lancellotti D
AD  - Respiratory Medicine, Hospital Privado de Comunidad, Mar del Plata, Argentina.
FAU - Malfante, P
AU  - Malfante P
AD  - Autoimmune Diseases Unit, Hospital Privado de Comunidad, Mar del Plata, 
      Argentina.
FAU - Babini, S
AU  - Babini S
AD  - Autoimmune Diseases Unit, Hospital Privado de Comunidad, Mar del Plata, 
      Argentina.
FAU - Sebastiani, J
AU  - Sebastiani J
AD  - Respiratory Medicine, Hospital Privado de Comunidad, Mar del Plata, Argentina.
FAU - Basso, V
AU  - Basso V
AD  - Autoimmune Diseases Unit, Hospital Privado de Comunidad, Mar del Plata, 
      Argentina.
FAU - Gaser, A
AU  - Gaser A
AD  - Department of Radiology, Instituto Diagnostico, Buenos Aires, Argentina.
FAU - Enghelmayer, J
AU  - Enghelmayer J
AD  - Respiratory Medicine, Hospital de Clinicas, Buenos Aires, Argentina.
FAU - Gandara, E
AU  - Gandara E
AD  - Department of Research, Hospital Privado de Comunidad, Mar del Plata, Argentina.
CN  - EPIMAR Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20181210
PL  - United States
TA  - Clin Immunol
JT  - Clinical immunology (Orlando, Fla.)
JID - 100883537
SB  - IM
MH  - Adult
MH  - Aged
MH  - Autoimmune Diseases/*drug therapy
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Lung Diseases, Interstitial/*drug therapy
MH  - Male
MH  - Middle Aged
OTO - NOTNLM
OT  - ANCA vasculitis
OT  - Dermatomyositis
OT  - Interstitial lung disease
OT  - Interstitial pneumonia with autoinmune features
OT  - Non-specific interstitial pneumonia
OT  - Organizing pneumonia
OT  - Rheumatoid arthritis
OT  - Systemic sclerosis
OT  - Usual interstitial pneumonia
EDAT- 2018/12/14 06:00
MHDA- 2019/12/04 06:00
CRDT- 2018/12/14 06:00
PHST- 2018/12/14 06:00 [pubmed]
PHST- 2019/12/04 06:00 [medline]
PHST- 2018/12/14 06:00 [entrez]
AID - S1521-6616(18)30723-X [pii]
AID - 10.1016/j.clim.2018.12.013 [doi]
PST - ppublish
SO  - Clin Immunol. 2019 Feb;199:52-56. doi: 10.1016/j.clim.2018.12.013. Epub 2018 Dec 
      10.